A prospective, open-label, one-arm clinical study of pemetrexed in combination with platinum-based regimens in patients with advanced non-squamous non-small cell lung cancer treated with apatinib after 4-6 cycles of chemotherapy
Status: Not yet recruiting
Phase of Trial: Phase IV
Latest Information Update: 23 Jan 2019
Price : $35 *
At a glance
- Drugs Pemetrexed (Primary) ; Rivoceranib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 11 Jan 2019 Planned End Date changed from 1 Dec 2020 to 1 Feb 2022.
- 11 Jan 2019 Planned primary completion date changed from 1 Sep 2020 to 1 Feb 2020.
- 11 Jan 2019 Planned initiation date changed from 1 Jan 2019 to 1 Feb 2019.